The FDA cleared a first “radioligand equivalent” generic to Novartis’ Lutathera, intensifying competition in a market previously dominated by brand leadership. Curium announced FDA approval of its radioligand equivalent, setting up a direct rivalry with Novartis’ established radioligand portfolio. The regulatory move comes as radioligand PSMA and neuroendocrine tumor imaging and therapy programs expand, and as payers and providers increasingly compare price and access for equivalent products. For developers and manufacturers, the clearance highlights how the FDA is operationalizing the “radioligand equivalent” concept—an important signal for future generics and follow-on products in theranostics.